Allosteric modulators of G protein-coupled receptors (GPCRs) have a number of potential advantages compared to agonists or antagonists that bind to the orthosteric site of the receptor. These include the potential for receptor selectivity, maintenance of the temporal and spatial fidelity of signaling in vivo, the ceiling effect of the allosteric cooperativity which may prevent overdose issues, and engendering bias by differentially modulating distinct signaling pathways. Here we describe the discovery, synthesis and molecular pharmacology of δ-opioid receptorselective positive allosteric modulators (δ PAMs). These δ PAMs increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as measured by receptor binding, G protein activation, β-arrestin recruitment, adenylyl cyclase inhibition and extracellular signal-regulated kinases (ERK) activation. As such, these compounds are useful pharmacological tools to probe the molecular pharmacology of the δ receptor and to explore the therapeutic potential of δ PAMs in diseases such as chronic pain and depression.
Introduction
The δ-opioid receptor is a seven transmembrane domain (7TMD) receptor that belongs to the Class A family of G protein coupled receptors (GPCRs). δ Receptor agonists have been shown to be antinociceptive especially in chronic pain models 1 , and to have potential as antidepressant agents 2 . The possible dual effects of δ receptor agonists to alleviate chronic pain and mitigate emotional disorders provide a particularly attractive therapeutic strategy because of the high level of comorbidity between chronic pain and depression. However, agonists acting directly at the δ receptor can show pro-convulsant effects in animal models, including non-human primates.
Indeed, it has been proposed that these seizurogenic properties of δ receptor agonists may be responsible for their antidepressant-like activity analogous to electro-convulsive therapy 3 . On the other hand, slowing the rate of administration of the δ receptor agonist SNC80 reduces seizurogenic activity but has no effect on anti-depressant -like effects 4 . Also, some δ receptor agonists (e.g. ADL5859) show no seizures in rat or mouse models 5 . These and other findings suggest that the convulsive properties of δ receptor agonists can be separated from their antidepressant-like effects 6 7 8 .
Allosteric modulators for GPCRs bind to a site on the receptor that is topographically distinct from the site that binds the orthosteric (or endogenous) agonist. Positive allosteric modulators (PAMs) increase the affinity and/or efficacy of bound orthosteric agonist ligands. The operational model of allosterism allows the quantification of allosteric effects and as such, it can estimate the binding affinity of the allosteric ligand to the free receptor (pK B ), the allosteric cooperativity factor (αβ) as well as any intrinsic agonist efficacy (τ B ) of the allosteric ligand. PAMs that have little or no intrinsic efficacy (τ B ) but modulate the orthosteric agonist response, have a number of advantages over orthosteric ligands 9 10 11 . In particular, these PAMs can theoretically maintain the temporal and spatial fidelity of endogenous receptor activation in vivo. The allosteric modulator binds to the target receptor but remains effectively silent until the endogenous orthosteric agonist is presented to the receptor. Therefore, PAMs can amplify the effect of endogenous signaling molecules without disrupting normal physiological regulation of receptor activation, and might therefore be expected to exhibit superior efficacy and side-effect profiles compared to traditional orthosteric agonists. Studies with δ receptor selective ligands, or utilizing a genetic deletion of the δ 5 receptor 1 , suggest that native opioid peptide signaling at the δ receptor mediates an increase in pain threshold in models of chronic pain and modulates mood states in rodent models 12 . Therefore, positive allosteric modulation of the δ receptor should enhance responses to the endogenous agonist peptides and thereby be therapeutically efficacious. In addition, the finite nature of the agonist potency shift (defined by the allosteric cooperativity factor), which saturates when the allosteric site is fully occupied, may increase the safety margin between therapeutic effect and possible side-effects associated with over-activation of the target receptor. Finally, and pertinent to the δ-receptor system which is known to exhibit ligand-biased signaling 13 , PAMs can modulate the signaling bias of receptor activation toward desired pathways or engender bias from previously unbiased ligands 14 15 . Thus, δ PAMs may provide a greater therapeutic window between pain relieving and antidepressant-like effects and proconvulsive activity, compared with traditional δ receptor orthosteric agonists.
In this study we report the synthesis and structure-activity relationship (SAR) of the first described δ PAMs. One of the most potent compounds identified, 3,3,6,6-tetramethyl-9-(4-((2-methylbenzyl)oxy)phenyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (2, BMS-986187), was further characterized in radioligand binding assays and using a range of cellular functional assays. 2 was shown to positively modulate orthosteric agonist binding affinity and functional potency at the δ receptor, and enhance the efficacy of the partial agonist TAN67.
Results

Discovery and Structure-Activity Relationship (SAR) of δ δ δ δ Receptor PAMs
The δ PAM chemotype was identified from a high throughput screen (HTS) using a β-arrestin recruitment assay in a PathHunter U2OS cell line coexpressing µ and δ receptors (U2OS-OPRM1D1) (DiscoveRx, Freemont, CA) 16 17 .
The screen was executed in PAM mode by measuring activity in the presence of an EC 10 concentration of both endomorphin-I (a µ receptor-selective agonist), and leu-enkephalin which in this assay and cell line was a relatively selective agonist for the δ receptor 18 . Typically, when using HTS approaches to identify PAMs, an EC 6 concentration of orthosteric agonist is used 19 . However, in this HTS the sum of the two EC 10 concentrations of agonists offered a compromise between the detection of both µ and δ receptor PAMs and the ability to maintain the overall signal window so that lower efficacy partial agonists could also be detected. Follow-up in vitro testing to determine structural features necessary for PAM activity was performed utilizing CHO-PathHunter cell-lines (CHO-OPRD1 and CHO-OPRM1) obtained from DiscoveRx. Concentration response curves (CRCs) for HTS hits were determined both in agonist mode (in the absence of orthosteric agonist) to determine agonist activity of the test compounds, and in PAM mode (in the presence of an EC 20 concentration of orthosteric agonist) to determine allosteric modulator activity using the β-arrestin recruitment assays. Compound 7 ( Table 1 ) was identified as a δ PAM, producing a robust potentiation of the response to an EC 20 concentration of leu-enkephalin.
As shown in Scheme 1, we synthesized a series of close analogs of 7 to optimize δ PAM potency and selectivity.
None of the compounds exhibited significant agonist activity in a β-arrestin recruitment assay, but all of the compounds produced measurable PAM activity at the δ receptor. 1 with an unsubstituted benzyl ring acted as a δ PAM with an EC 50 value of 0.2 µM and showed 30-fold selectivity in the β-arrestin recruitment assay compared with PAM activity at the µ receptor. Introduction of a methyl group in various positions around the phenyl ring (2-4) suggested that ortho substitution increased δ receptor PAM activity by an order of magnitude, with minimal effect on µ receptor PAM activity, while meta and para substitution did not significantly affect δ or µ receptor PAM activity. The corresponding ortho-F analog 5 was not significantly more active than 1, suggesting that the increased δ receptor activity with the o-methyl was due to a steric rather than an electronic effect. Similarly, the meta-and para-F analogs 6-7, or the ortho-Cl analog 8 did not afford an increase in δ receptor activity.
Introduction of a second Cl-group in the meta position (9) provided a modest improvement in δ receptor activity while maintaining selectivity. A more pronounced effect was observed with the ortho-Br analog 10 which produced equipotent PAM activity to 2 at the δ receptor, but no observable PAM activity at the µ receptor, suggesting that 9-(4-((2-bromobenzyl)oxy)phenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (10, BMS-986188) is the most δ receptor-selective analog we have identified to date. The effect of 7 ortho substitution on δ receptor PAM potency and selectivity appears to be restricted to small substituents. As shown with analogs 11-15, larger ortho substituents did not improve δ PAM activity and had no effect on selectivity. Similarly, more drastic changes to the chemotype, such as increasing the chain length between the ether oxygen and the phenyl ring, or replacement of the benzyl ether with a phenyl amide, yielded a significant loss in δ receptor PAM activity (data not shown). The most potent δ PAM identified was 2, which in the presence of an EC 20 of leu-enkephalin, produced a β-arrestin response with an average EC 50 of 33 nM in CHO-OPRD1 cells (Table 1) . Representative agonist and PAM mode CRCs for 2 at the µ and δ receptor are shown in Figure 1 . values at the δ opioid receptor ( Figure S1 ). Similarly, the molecular weight of the molecule (mol.MW), the Van der Waals surface area of polar nitrogen and oxygen atoms and carbonyl carbon atoms (PSA), and the number of nitrogen and oxygen atoms (X.N and O) were identified as the best predictors for EC 50 values at the µ opioid receptor ( Figure S2 ). An estimation of the δ/µ selectivity based on the ratio of the predicted EC 50 values at the δ and µ opioid receptors revealed a definite separation between compounds with a selectivity above or below a 33-fold cutoff ( Figure S3 ).
Binding Characterization of 2
8 2 (at concentrations up to 30 µM) does not inhibit binding of the orthosteric antagonist 3 H-diprenorphine (DPN) to CHO-hDOPr cell membranes suggesting that 2 is acting at an allosteric site to produce agonist and PAM activity ( Figure 2A ). However, in competition binding experiments 10 µM of 2 increased the affinity of the orthosteric agonists, leu-enkephalin ( Figure 2B ), SNC80 ( Figure 2C ) and TAN67 ( Figure 2D ) to displace 3 H-DPN. This suggests that 2 is an affinity modulator (the α component of the cooperativity factor) in the system tested ( Table 2 ). The affinity shift with the partial agonist TAN67 is less than that seen with the full agonists leu-enkephalin and SNC80
( Table 2 ).
Functional Characterization of 2
The PAM activity of 2 was further characterized in four different functional assays. In the CHO-OPRD1 PathHunter cells, 2 effects on leu-enkephalin potency and efficacy were studied in both β-arrestin recruitment assays and inhibition of forskolin-stimulated cAMP accumulation assays. Unlike the U2OS cell lines used in the HTS, where forskolin was relatively ineffective at stimulating adenylyl cyclase activity, the recombinant CHO PathHunter cell lines allowed us to investigate both β-arrestin recruitment and inhibition of forskolin-stimulated cAMP accumulation in the same cell line. In the β-arrestin recruitment assay, 2 alone (up to 10 µM) produced only marginal agonist activity (~10% of a maximal response to leu-enkephalin) but produced a robust 18-fold increase in the potency of leu-enkephalin ( Figure 3A) . A small increase in the maximal response to leu-enkephalin with 2, relative to leu-enkephalin alone, was also observed. This suggests that 2 is a PAM with little or no intrinsic efficacy in this system. In contrast, in the inhibition of forskolin-stimulated cAMP assay, 2 alone produced robust activity resulting in full inhibition of cAMP accumulation at concentrations above 3 µM ( Figure 3B ). At lower concentrations, 2 increased the potency of leu-enkephalin. At a 370 nM concentration of 2 (the highest concentration at which a potency for leu-enkephalin could be determined) the potency of leu-enkephalin was increased by 56-fold. Similar findings were observed using the small molecule orthosteric agonist SNC80 in these two assays (Table 3) . Similar to the findings in the cAMP functional assay, 2 was also shown to be a PAM in [ at the δ receptor in the absence of orthosteric agonist i.e. at the free receptor) were determined for 2 across these different assays and with different orthosteric agonists ( Table 3) .
The mean ± SEM pK B across all the assays for 2 was 6.02 ± 0.16 (~1 µM). One would expect that the pK B values should be the same across all the cell-lines, functional assays, and orthosteric agonists used, since the pK B represents the binding affinity of 2 to the free receptor. Two way ANOVA with multiple comparison test of the pK B values in Table 3 showed no significant difference between the different orthosteric agonist ligands used in the same functional assay. For SNC80 and TAN67 there were also no significant differences in pK B values across the different functional pathways tested. However, for leu-enkephalin there were significant differences in the pK B values between β-arrestin recruitment and [ 
Discussion
Using a β-arrestin recruitment assay, the SAR of a δ PAM chemotype identified from HTS was explored, resulting in identification of compounds (1-15) with little or no agonist activity, but which produced PAM activity at the δ and with the allosteric cooperativity, the large proportion of the analogs tested exhibited efficacy close to or above 100% limiting the usefulness of the Y max parameter for selecting compounds for further study. Instead, potency of the PAM response was used and selectivity was determined using potency ratios between the PAM responses at the δ receptor compared to the µ receptor. While this procedure is useful for selecting δ receptor selective PAM candidates to pursue, one must bear in mind that different orthosteric agonist ligands were used in the PAM mode assays; leu-enkephalin for the δ receptor, and endomorphin-I for the µ receptor. Since we currently know little about the possible probe dependence of these PAM compounds at the δ and µ receptor we cannot necessarily assume that the reported selectivity will be the same with different orthosteric probe ligands.
The selected dataset used for multivariate statistical analysis does not allow for thorough cross-validation of the presented linear models, but our results suggest initial physicochemical properties that can be used as searching criteria for additional compounds with potential PAM activity at δ and µ opioid receptors. 2 was selected for further characterization since it had the highest PAM mode potency at the δ receptor and showed 100-fold selectivity compared to the µ receptor.
The multi-variate statistical analysis initially suggested that the compounds may not be readily soluble in aqueous buffer at concentrations in the micromolar range. Also, nephelometry data (not shown) suggest that 2 and 10
show particulate matter in phosphate-buffered saline solution at concentrations above 1 µM. When nephelometry was repeated using the specific buffer used for the β-arrestin recruitment assays (HBSS +25 mM HEPES and 10% FBS) in Table 1 , 2 and 10 produced particulate matter above 3 µM. While the majority of responses to 2 in cells expressing the δ receptor were maximal at 1 µM (and therefore, within the solubility window predicted for 2), the µ receptor responses (e.g. see Figure 1 ) also showed sigmoidal responses (i.e. the responses were not biphasic) up to 30 µM of 2, suggesting that solubility was not an issue in these assays in the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 specific buffers used. However, compound solubility should be an important consideration in further studies and optimization of this chemical series.
From competition binding studies, 2 did not affect 3 H-DPN binding to the δ receptor, but increased the affinity of orthosteric agonists suggesting that 2 does not bind to the orthosteric site of the δ receptor but can increase the affinity of orthosteric agonists binding to the receptor (α cooperativity). The precise mechanism for this cooperativity remains unknown. However, in this context it is tempting to make comparisons to recently discovered PAMs of the μ opioid receptor 21 . The μ receptor PAM 2-(3-bromo-4-methoxyphenyl)-3-((4-chlorophenyl)sulfonyl)thiazolidine (16, BMS-986122) has been found to differentially increase the affinity of various orthosteric agonists, and the magnitude of the affinity increase (α value) produced by 16 correlates with the intrinsic activity of the orthosteric ligand used 22 . The mechanism by which 16 induces this affinity modulation is suggested to be via reducing the affinity of Na + for its binding site on the µ receptor. The precise binding site for 16 on the μ receptor has not been clearly established and it is unknown whether the δ receptor PAMs described here bind to an analogous binding site on the δ receptor, or act via a similar mechanism. However, several analogs of 16 were found to exhibit weak activity at δ receptors 21 , and most of the δ receptor PAMs described here also exhibit some degree of activity at μ receptors. Therefore, it is possible that these δ receptor PAMs may be binding to a site on the δ receptor that is analogous to the 16 binding site on the μ receptor, and may work through a similar mechanism. The reduced affinity shift observed with 2 for the partial agonist TAN67 compared with the agonists with higher intrinsic activity, Leu-enkephalin and SNC80 ( Figure 2 , Table 2 ), is consistent with this hypothesis. It will be interesting to determine whether these δ PAMs reduce the affinity of Na + for its binding site on the δ receptor. Sodium ions are known to stabilize a lower affinity state of the δ receptor, and the molecular basis for allosteric Na + control of opioid receptor signaling has been elucidated recently 23 24 .
While TAN67 was a partial agonist in the CHO-hDOPr cell line for [ response, it had even less intrinsic activity in a C6-DOPr cell-line at 41% of maximal SNC80 response (data not shown). In the presence of 2 (300 nM), the maximal stimulation by TAN67 was increased to 67% of maximal 12 SNC80 response. This suggests that 2 has some allosteric efficacy cooperativity (β), as well as the affinity cooperativity (α) observed above.
In all of the functional assays, 2 acted as a PAM, increasing the potency of the response to orthosteric agonists.
No activity was observed in functional assays when 2 was added alone in CHO-parental cells (lacking the recombinant δ opioid receptor) in either the ERK activation assay or cAMP assay (data not shown). However, in cells expressing the δ receptor, 2 (when added alone) produced significant activity in cAMP inhibition, [
S]GTPγS
binding and ERK activation assays, suggesting that this activity is due to intrinsic efficacy of 2 at the δ receptor.
Thus, 2 is a PAM-agonist in these systems 25 . In cells expressing the δ receptor, 2 showed little to no agonist activity in the β-arrestin recruitment assay, which measures an event proximal to receptor activation with limited signal amplification. The difference in observed agonist activity for 2 between the β-arrestin recruitment assay and the cAMP assay ( Figure 3 ) is likely reflective of a higher level of signal amplification and thus a higher receptor reserve in the cAMP assay compared to the β-arrestin recruitment assay in the same cell-line 26 27 .
Phosphorylation of the receptor by G protein-coupled receptor kinases (GRKs) is thought to be a prerequisite for β-arrestin recruitment 28 . It would be interesting to see how 2 impacts δ receptor phosphorylation by GRKs and consequently, desensitization and internalization of the receptor.
Calculation of pK B values for 2 across the various functional assays with leu-enkephalin, SNC80 and TAN67, using the allosteric operational model, showed some variability. These differences in pK B values may result from the allosteric effect not reaching a plateau or ceiling. This could reflect that the allosteric effect was sub-maximal at concentrations below those at which full agonism was observed with 2, or that the highest concentrations of 2 used did not cause the allosteric EC 50 shift to reach its ceiling. This can make accurate assessment of the allosteric parameters more difficult to estimate in the model. Other variables, including the use of different cell lines, or use of a tagged receptor (in the case of the PathHunter CHO-OPRD1 cell line) may also contribute to the variability of values obtained in the model.
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The fact that we observed PAM effects with 2 at concentrations lower than those which produced agonist effects is entirely consistent with the allosteric ternary complex model, because the former (PAM effects) are observed in the presence of orthosteric agonist, and hence the affinity of the modulator for the receptor is higher, whereas the latter (agonist effects) reflect the actions of the modulator at the free receptor and thus require higher concentrations to achieve the same level of fractional occupancy. Therefore, a PAM with a large cooperativity factor (αβ) can exhibit functional activity that is far more potent than its K B value. This has potential implications for PAM drug discovery programs, suggesting that it is important to track functional PAM activity, rather than K B values, when designing assays to support SAR. Additionally, this suggests that assays assessing target engagement may dramatically underestimate the relevant receptor occupancy of a PAM, since the affinity of the PAM (and therefore its fractional receptor occupancy) will be much higher at sites where orthosteric agonist is present.
While such sites may represent only a small fraction of the receptor population in vivo, they nonetheless represent the relevant receptor population, since positive allosteric modulation can only occur when and where orthosteric agonist is bound.
Despite the complexities discussed above, all available data suggests that 2 is a δ PAM or a δ PAM-agonist. In future studies, it will be important to confirm the activity of 2 and its analogs in cells or tissues natively expressing δ receptors. Further, it will be of significant interest to determine whether compounds such as 2 also exhibit direct agonist activity in native systems expressing endogenous levels of δ receptors. PAMs devoid of intrinsic agonist activity could theoretically have therapeutic advantages over PAM-agonists, particularly in the maintenance of the temporal and spatial fidelity of endogenous receptor activation in vivo, as they would effectively be silent when bound to the receptor until orthosteric (endogenous) agonist is presented to the receptor. A key issue will be the determination of these effects in vivo. We intend to evaluate the in vivo activity of 2 and its analogs in models of acute and chronic pain 29 , migraine 30 , depression 31 , and convulsive activity 3 which is a known liability of δ opioid receptor agonists that has limited the pursuit of δ receptor agonists as potential therapeutics. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 In summary, we have identified and characterized δ receptor-selective PAMs including our lead compound 2.
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Further studies are planned to assess probe dependence and signaling bias for these PAMs using a variety of orthosteric opioid receptor ligands and functional assays. Additional research is also ongoing to determine if this new class of compounds could represent a viable approach to develop new medicines for chronic pain, depression and other therapeutic indications. 
Synthesis of Analogs 1-15:
General Procedure. To a solution of 9-(4-hydroxyphenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16
Two analytical LC/MS injections were used to determine the final purity: Injection 1 conditions: Column: Waters The yield of the product was 20.6 mg, and its estimated purity by LCMS analysis was 100%. 1 
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FlpIn CHO cells were transfected with the pOG44 vector encoding Flp recombinase and the pDEST vector encoding the human δ receptor (hDOPr) at a ratio of 9:1 using polyethylenimine as transfection reagent. 24 h after transfection the cells (CHO-hDOPr) were subcultured and the medium was supplemented with 700 μg/mL
HygroGold as selection agent. Cells were grown and maintained in DMEM containing 20 mM HEPES, 5% fetal bovine serum and 200 μg/mL Hygromycin-B. Cells were maintained at 37 °C in a humidified incubator containing 5% CO 2 . These cells were used for ERK phosphorylation assays and membranes derived from these cells were used for [ 
Materials:
PathHunter detection reagents were from DiscoveRx (Freemont, CA). Cell culture media and supplements were from Life Technologies (Carlsbad, CA). Lance-Ultra cAMP detection reagents, Surefire ERK assay reagents, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Incubations were terminated by the addition of 2 µL PathHunter Reagent (DiscoveRx). One hour later luminescence was detected using a Viewlux imaging plate reader (PerkinElmer).
Inhibition of Forskolin-Stimulated cAMP Accumulation Assays.
CHO-OPRD1 cells were grown to confluence (as described above). Cells were harvested and resuspended at 1e Characterization of δ-opioid receptor-selective PAMs in the CHO-OPRD1 cAMP assay, using curve-shift assays, were performed as described above using orthosteric agonists described in the Results & Discussion.
Membrane Preparation
Confluent cells were rinsed with phosphate-buffered saline and then detached using harvesting buffer (0.68 mM EDTA, 0.15 M NaCl, 20 mM HEPES, pH 7.4). Cells were pelleted by centrifugation at 300 x g for 3 min, followed by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20 resuspension in cold 50 mM Tris-HCl buffer, pH 7.4. Pellet was rehomogenized using a Tissue Tearor and then centrifuged at 20,000 x g for 20 min at 4 °C. The supernatant was discarded and the process was repeated for an additional rehomogenization and centrifugation. The supernatant was discarded and the final pellet was resuspended in 50 mM Tris-HCl and flash frozen in aliquots using liquid nitrogen. Aliquots were kept -80 °C until assays. Protein concentration was determined using BCA protein assay with bovine serum albumin as the standard.
Radioligand Binding Assay
Cell membranes (as prepared above, 10µg/well) were incubated in the following mixture for 90 minutes at 25 °C: 
Data Analysis
For all experiments data were analyzed and EC 50 or Ki values determined using nonlinear regression analysis to fit a logistic equation using GraphPad Prism version 6 (GraphPad, San Diego, CA). pK B and αβ values were determined using the "Operational Model of Allosterism" 20 (see (1) below), using Graphpad Prism version 6.
Within this model, E is the pharmacological effect, K A and K B denote the equilibrium binding constants for the orthosteric ligand, A, and the allosteric ligand, B, at the receptor. The binding cooperativity factor, α represents the effect of the allosteric ligand on orthosteric agonist binding affinity, and vice versa. An activation cooperativity factor, β, denotes the effect the allosteric ligand has on orthosteric agonist efficacy. Agonism constants τ A and τ B , represent the intrinsic activity of the orthosteric agonist and any intrinsic activity of the allosteric ligand, 22 respectively, which is dependent on the cell context and receptor expression level of the cell system, and intrinsic efficacy of the ligands used. The remaining parameters, Em and n, denote the maximal response of the system, and the slope, respectively.
23
Figure 1 Data are presented as the mean ± SEM, n=4. Table 1 Structure activity relationship of the δ-PAM chemotype in PathHunter CHO-OPRD1 and CHO-OPRM1 cells in a β- Table 2 . Data are presented as the mean ± SEM of 3 experiments. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 24 Effect of 2 (10 µM) on orthosteric agonist competition binding Ki values in CHO-hDOPr cell membranes. 2 had no effect on 3 H-DPN binding (see Figure 2 ) but increased the affinity of orthosteric agonist competition binding curves. Data are presented as the mean ± SEM of 3 experiments. Table 3 ). represent the basal response and the maximal response produced, respectively. In the pERK assay, 0 % represents basal activity in serum-free media and 100 % represents the pERK response in the presence of 10 % serum. Data are presented as the mean ± SEM, n = 3 to 7. Data were fitted to the operational model of allosterism (see Table   3 ). Table 3 Allosteric parameters for 2 at the δ receptor. Values for affinity, efficacy, and allosteric cooperativity for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 25 orthosteric agonist and allosteric modulator, respectively; pK A and pK B represent the binding affinity of the orthosteric agonist and the allosteric modulator, respectively, to the free receptor; and αβ represents the composite allosteric cooperativity factor. Data are presented as the mean ± SEM of 3 to 7 expts.
* pK A is fixed to its equilibrium binding affinity as ligand is a full agonist in all endpoints tested ** the pK A of Leu-enkephalin and TAN67 in endpoints where they are partial agonists was obtained from fitting their CRC to the operational model of agonism to obtain a functional affinity in each endpoint tested.
*** the pK B for TAN67 in [ 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 29 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42 
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